2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005

News and Resources

2012 Releases

12/14/2012 - Opexa Therapeutics Announces Reverse Stock Split

11/14/2012 - Opexa Therapeutics Reports First Quarter 2012 Financial Results and Provides Corporate Update

11/13/2012 - Opexa Receives Clinical Trial Approval from Health Canada for Novel T-Cell Therapy

11/12/2021 - Opexa Therapeutics to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

11/05/2022 - Opexa Announces Agreements for up to $16.5 Million in Equity Commitments

09/17/2012 - Opexa to Participate at UBS Global Life Sciences Conference

09/12/2021 - Opexa Intiates Late Stage Clinical Study of Tcelna in Patients with Secondary Progressive Multiple Sclerosis (SPMS)

09/10/2021 - Opexa to Participate at Upcoming Industry Conferences

08/13/2012 - Opexa Therapeutics Reports First Quarter 2012 Financial Results and Provides Corporate Update

07/26/2012 - Opexa Therapeutics Closes Secured Note Financing

05/21/2012 - Opexa Announces Tcelna as New Brand Name for MS Therapy

05/11/2021 - Opexa Therapeutics Reports First Quarter 2012 Financial Results and Provides Corporate Update

04/19/2012 - Opexa to Hold Preliminary Investigator's Meeting for MS Trial at American Academy of Neurology Annual Meeting

02/29/2012 - Opexa Therapeutics Executes Strategic Service Agreement with Pharmaceutical Research Associates to Manage Clinical Trial

02/27/2012 - Opexa Therapeutics Reports Year End 2011 Financial Results and Provides Corporate Update

02/08/2022 - Opexa Therapeutics to Present at the 14th Annual BIO CEO & Investor Conference

01/17/2012 - Opexa Therapeutics to Present at the BOCEMb; Noble Financial Capital Markets' Eighth Annual Equity Conference